VIR vs. FDMT, CGEM, TARS, SRRK, NMRA, ADMA, BCRX, AUTL, MESO, and IMTX
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include 4D Molecular Therapeutics (FDMT), Cullinan Oncology (CGEM), Tarsus Pharmaceuticals (TARS), Scholar Rock (SRRK), Neumora Therapeutics (NMRA), ADMA Biologics (ADMA), BioCryst Pharmaceuticals (BCRX), Autolus Therapeutics (AUTL), Mesoblast (MESO), and Immatics (IMTX). These companies are all part of the "biological products, except diagnostic" industry.
4D Molecular Therapeutics (NASDAQ:FDMT) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.
4D Molecular Therapeutics has a net margin of -436.30% compared to 4D Molecular Therapeutics' net margin of -677.69%.
99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 15.6% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Vir Biotechnology received 6 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. However, 64.71% of users gave 4D Molecular Therapeutics an outperform vote while only 48.15% of users gave Vir Biotechnology an outperform vote.
4D Molecular Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vir Biotechnology had 8 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 15 mentions for Vir Biotechnology and 7 mentions for 4D Molecular Therapeutics. Vir Biotechnology's average media sentiment score of 1.04 beat 4D Molecular Therapeutics' score of 0.65 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.
4D Molecular Therapeutics presently has a consensus target price of $44.22, indicating a potential upside of 72.07%. Vir Biotechnology has a consensus target price of $33.57, indicating a potential upside of 255.63%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than 4D Molecular Therapeutics.
4D Molecular Therapeutics has a beta of 2.94, indicating that its share price is 194% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.
Summary
4D Molecular Therapeutics beats Vir Biotechnology on 10 of the 17 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
